Research programme: protein misfolding disease therapeutics - Protego Biopharma
Alternative Names: Proteostasis-deficiencies therapeutics - Protega BiopharmaLatest Information Update: 01 Dec 2021
At a glance
- Originator Protego Biopharma
- Class Small molecules
- Mechanism of Action Protein folding stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders